Effect of the exosome-mediated suppression of the estrogen signaling: the role in the progression of the hormonal resistance of breast cancer cells
D. V. Sorokin,
O. E. Andreeva,
E. I. Mikhaevich,
Yu. Yu. Shchegolev,
A. M. Scherbakov,
M. V. Gudkova,
M. A. Krasil’nikov https://doi.org/10.17650/2313-805X-2020-7-3-58-62
Abstract
The most effective treatment of the hormone-dependent breast cancer is based on the antiestrogens SERM and aromatase inhibitor treatment, however its efficiency is limited by the acquired resistance to the drugs.
Previously we have revealed the effect of the transferring of the hormonal resistance from the resistant to the sensitive cells under in vitro cell co-cultivation, and demonstrated exosomes involvement in this process. Here we have shown that the exosomes of the resistant cells caused the marked inhibition of the estrogen signaling in the recipient cells, and identified microRNAs – ERα suppressors that overexpressed in the resistant exosomes.
Taken together, the results obtained demonstrate the important role of the estrogen signaling suppression in the exosome-induced transferring of the hormonal resistance, and revealed the involvement of the exosomal microRNA in the ERα down-regulation.
About the Authors
D. V. Sorokin
НИИ канцерогенеза ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава России
Russian Federation
Russian Federation
O. E. Andreeva
Research Institute of Carcinogenesis, N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Build. 15, 24 Kashirskoe Shosse, Moscow 115478, Russia
Russian Federation
Build. 15, 24 Kashirskoe Shosse, Moscow 115478, Russia
E. I. Mikhaevich
Research Institute of Carcinogenesis, N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Build. 15, 24 Kashirskoe Shosse, Moscow 115478, Russia
Russian Federation
Build. 15, 24 Kashirskoe Shosse, Moscow 115478, Russia
Yu. Yu. Shchegolev
Research Institute of Carcinogenesis, N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Build. 15, 24 Kashirskoe Shosse, Moscow 115478, Russia
Russian Federation
Build. 15, 24 Kashirskoe Shosse, Moscow 115478, Russia
A. M. Scherbakov
Research Institute of Carcinogenesis, N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Build. 15, 24 Kashirskoe Shosse, Moscow 115478, Russia
Russian Federation
Build. 15, 24 Kashirskoe Shosse, Moscow 115478, Russia
M. V. Gudkova
Research Institute of Carcinogenesis, N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Build. 15, 24 Kashirskoe Shosse, Moscow 115478, Russia
Russian Federation
Build. 15, 24 Kashirskoe Shosse, Moscow 115478, Russia
M. A. Krasil’nikov
Research Institute of Carcinogenesis, N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Build. 15, 24 Kashirskoe Shosse, Moscow 115478, Russia
Russian Federation
Build. 15, 24 Kashirskoe Shosse, Moscow 115478, Russia
References
1. Semina S.E., Rudenskaya E.A., Mittenberg A.G. et al. Exosomes and development of cancer cell resistance to metformin: pilot study. Uspekhi molekulyarnoy onkologii = Advances in Molecular Oncology 2017;4(3):92–8. (In Russ.)]. DOI: 10.17650/2313-805X-2017-4-3-92-98.
2. Semina S.E., Scherbakov A.M., Vnukova A.A. et al. Exosome-mediated transfer of cancer cell resistance to antiestrogen drugs. Molecules 2018;23(4):829. DOI: 10.3390/molecules23040829.
3. Semina S.E., Barlev N.A., Mittenberg A.G., Krasil’nikov M.A. Comparative analysis of the exosomal cargo of the estrogenresistant breast cancer cells. Sibirskiy onkologicheskiy zhurnal = Siberian Journal of Oncology 2018;17(4):36–40. (In Russ.)]. DOI: 10.21294/1814-4861-2018-17-4-36-40.
4. Reid G., Hubner M.R., Metivier R. et al. Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell 2003;11(3):695–707. DOI: 10.1016/s1097-2765(03)00090-x.
5. McAndrew N.P., Finn R.S. Management of ER positive metastatic breast cancer. Semin Oncol 2020. DOI: 10.1053/j.seminoncol.2020.07.005.
6. Spinello A., Ritacco I., Magistrato A. Recent advances in computational design of potent aromatase inhibitors: open-eye on endocrine-resistant breast cancers. Expert Opin Drug Discov 2019;14(10):1065–76. DOI: 10.1080/17460441.2019.1646245.
7. El Sayed R., El Jamal L., El Iskandarani S. et al. Endocrine and targeted therapy for hormone-receptor-positive, HER2-negative advanced breast cancer: insights to sequencing treatment and overcoming resistance based on clinical trials. Front Oncol 2019;9:510. DOI: 10.3389/fonc.2019.00510.
8. Clarke R., Tyson J.J., Dixon J.M. Endocrine resistance in breast cancer – an overview and update. Mol Cell Endocrinol 2015;418(Pt 3(0–3)):220–34. DOI: 10.1016/j.mce.2015.09.035.
9. Suba Z. The pitfall of the transient, inconsistent anticancer capacity of antiestrogens and the mechanism of apparent antiestrogen resistance. Drug Design, Develop Ther 2015;9:4341–53. DOI: 10.2147/dddt.s89536.
10. Viedma-Rodríguez R., Baiza-Gutman L., Salamanca-Gómez F. et al. Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (review). Oncol Rep 2014;32(1):3–15. DOI: 10.3892/or.2014.3190.
11. Semina S.E., Scherbakov A.M., Kovalev S.V. et al. Horizontal transfer of tamoxifen resistance in MCF-7 cell derivates: proteome study. Cancer Invest 2017;35(8):506–18. DOI: 10.1080/07357907.2017.1368081.
12. Shchegolev Y., Sorokin D., Scherbakov A. et al. Upregulation of Akt/Raptor signaling is associated with rapamycin resistance of breast cancer cells. Chem Biol Interact 2020;330:109243. DOI: 10.1016/j.cbi.2020.109243.
13. Zhang W.L., Zhang J.H. miR-181c promotes proliferation via suppressing PTEN expression in inflammatory breast cancer. Int J Oncol 2015;46(5):2011–20. DOI: 10.3892/ijo.2015.2896.
14. Zhuang L., Qu H., Cong J. et al. MiR-181c affects estrogen-dependent endometrial carcinoma cell growth by targeting PTEN. Endocr J 2019;66(6):523–33. DOI: 10.1507/endocrj.EJ18-0538.
Review
For citations:
Sorokin D.V., Andreeva O.E., Mikhaevich E.I., Shchegolev Yu.Yu., Scherbakov A.M., Gudkova M.V., Krasil’nikov M.A. Effect of the exosome-mediated suppression of the estrogen signaling: the role in the progression of the hormonal resistance of breast cancer cells. Advances in Molecular Oncology. 2020;7(3):58-62. (In Russ.) https://doi.org/10.17650/2313-805X-2020-7-3-58-62
Views:
655
Email this article 